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SUPPLEMENTARY MATERIALS 
SUPPLEMENTARY METHODS 
Patients and study design 
The TEAM trial inclusion and exclusion criteria differed slightly by participating 
country. Eligible patients were postmenopausal women with HRec-positive breast cancer 
(defined locally), with histologically or cytologically confirmed T1-3 N0-2 M0 
adenocarcinoma and adequate local therapy (surgical resection +/- radiotherapy) and/or 
chemotherapy. The United Kingdom/Ireland (1053/1275; 82.5%), the Netherlands 
(2710/2753; 98.4%), Belgium (113/414; 27.3%), Germany (670/1471; 45.5%), and Greece 
(85/207; 41.1%) provided eligible tumour samples from surgical resections for tissue 
microarray (TMA; n=4631) construction with linked clinicopathological data. This study 
hypothesised that low expression of our biomarkers would predict response to exemestane 
alone.  
Procedures 













167/IKKα/p65536/N-Ras/Raf-1338) or 10% Casein (p44/42 
MAPK
202/204
) was the blocking solution. TMA sections were incubated at 37ºC with primary 
ER
118
 (1:500, Cell Signaling Ltd, #2511), ER
167
 (1:200, Cell Signaling Ltd, #5587), IKKα 
(1:800, Geneway, #GTW662250), p65
536
 (1:50, Abcam, #ab28856), Raf-1
338
 (1:300, 
Millipore, #05-538), and p44/42 MAPK
202/204 
(1:600, Cell Signaling Ltd, #4376) or at 42ºC 
with primary N-Ras (1:30, Santa Cruz, #SC-51). HRP-multispecies secondary antibody 
(Roche) followed by DAB substrate for color development. Slides were counterstained with 
hematoxylin.  
Stained TMA sections were scanned using a Hamamatsu NanoZoomer at x20 
magnification and visualized on Slidepath Digital Image Hub (Leica Biosystems). The 
weighted histoscore is calculated as follows: 0x% not stained + 1x% weakly stained + 2x% 
moderately stained + 3x% strongly stained and gives a range from 0 to 300. 
Supplementary Table 1. Biomarker associations with common clinicopathological factors 
 
Clinicopathological factors 
ER167 (n=4133) IKK alpha (n=3024) Raf-1338 (n=4030) p44/42 MAPK202/204 (n=4055) 































































































































































































































































































































































P values were calculated using a two-sided Chi-square test.  
